Get the Stockscreener App
114.14
0.25%
-0.29
After Hours:
114.00
-0.14
-0.12%
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Abbott Laboratories stock is traded at $114.14, with a volume of 5.78M.
It is down -0.25% in the last 24 hours and up +12.28% over the past month.
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives roughly 60% of sales outside the United States.
See More
Previous Close:
$114.43
Open:
$114
24h Volume:
5.78M
Relative Volume:
0.50
Market Cap:
$197.51B
Revenue:
$46.59B
Net Income/Loss:
$5.41B
P/E Ratio:
36.89
EPS:
3.0938
Net Cash Flow:
$7.38B
1W Performance:
+2.58%
1M Performance:
+12.28%
6M Performance:
+1.72%
1Y Performance:
-13.82%
1-Day Range:
$113.99
$115.23
1-Week Range:
$109.35
$115.67
52-Week Range:
$81.97
$137.49
Abbott Laboratories Stock (ABT) Company Profile
Name
Abbott Laboratories
Sector
Industry
Phone
(224) 667-6100
Address
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Compare ABT vs SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
114.14 | 198.01B | 46.59B | 5.41B | 7.38B | 3.0938 |
SYK
Stryker Corp
|
327.70 | 130.41B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
92.30 | 120.48B | 36.36B | 4.84B | 5.43B | 3.7261 |
BSX
Boston Scientific Corp
|
49.37 | 75.37B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
89.83 | 53.19B | 6.30B | 1.07B | 1.09B | 1.8406 |
Abbott Laboratories Stock (ABT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-22-26 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Oct-10-25 | Initiated | The Benchmark Company | Buy |
| Jul-18-25 | Upgrade | Jefferies | Hold → Buy |
| Jun-16-25 | Initiated | Leerink Partners | Market Perform |
| Oct-08-24 | Initiated | Oppenheimer | Outperform |
| Sep-19-24 | Initiated | Piper Sandler | Overweight |
| Jul-30-24 | Downgrade | Edward Jones | Buy → Hold |
| May-30-24 | Initiated | Goldman | Buy |
| Jul-21-23 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| May-30-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-20-23 | Reiterated | Barclays | Overweight |
| Apr-20-23 | Reiterated | Bernstein | Outperform |
| Apr-20-23 | Reiterated | JP Morgan | Overweight |
| Apr-20-23 | Reiterated | Raymond James | Outperform |
| Apr-20-23 | Reiterated | UBS | Buy |
| Apr-20-23 | Reiterated | Wolfe Research | Underperform |
| Mar-29-23 | Initiated | UBS | Buy |
| Oct-26-22 | Initiated | Mizuho | Neutral |
| Oct-18-22 | Initiated | Barclays | Overweight |
| Oct-12-22 | Initiated | Jefferies | Hold |
| Jul-06-22 | Initiated | Wolfe Research | Underperform |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Jan-27-22 | Reiterated | Credit Suisse | Outperform |
| Jan-27-22 | Reiterated | Morgan Stanley | Overweight |
| Jan-27-22 | Reiterated | Raymond James | Outperform |
| Jan-27-22 | Reiterated | UBS | Buy |
| Dec-10-21 | Initiated | RBC Capital Mkts | Outperform |
| Oct-27-21 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Oct-14-21 | Initiated | Redburn | Neutral |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-15-21 | Initiated | Atlantic Equities | Neutral |
| Jan-28-21 | Upgrade | BTIG Research | Neutral → Buy |
| Sep-11-20 | Initiated | Wolfe Research | Outperform |
| Jun-01-20 | Downgrade | Goldman | Neutral → Sell |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Feb-13-20 | Initiated | Goldman | Neutral |
| Feb-06-20 | Resumed | BTIG Research | Neutral |
| Jan-02-20 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-13-19 | Reiterated | BofA/Merrill | Buy |
| Feb-07-19 | Reiterated | BofA/Merrill | Buy |
| Jan-02-19 | Downgrade | Citigroup | Neutral → Sell |
| Nov-30-18 | Upgrade | Goldman | Neutral → Buy |
| Oct-16-18 | Initiated | Barclays | Overweight |
| Jun-27-18 | Initiated | Bernstein | Outperform |
| Jan-30-18 | Reiterated | Citigroup | Neutral |
| Jan-25-18 | Reiterated | Stifel | Buy |
| Jan-25-18 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jan-03-18 | Initiated | Evercore ISI | Outperform |
| Jan-02-18 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-02-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-19-17 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-19-17 | Reiterated | Stifel | Buy |
View All
Abbott Laboratories Stock (ABT) Latest News
Abbott Will Pay $670 Million To End 2,000 Infant Formula Claims - NDTV Profit
Did Abbott’s Q2 Beat and Profit Hike Just Shift Abbott Laboratories’ (ABT) Investment Narrative? - simplywall.st
Abbott to pay $670 million to settle some preterm infant formula cases - Reuters
Abbott Reaches $670 Million Settlement in Infant Formula Litigation - Devdiscourse
Can Abbott Laboratories (ABT)’s Instinct Sensor Give MiniMed Group (MMED) a Competitive Edge? - Yahoo Finance
Abbott Laboratories Reaches $670 Million Settlement in NEC Infant Formula Lawsuits - Kalkine Media
Abbott Laboratories to pay $670 million to settle cases, claims over its formula for premature babies - Chicago Tribune
Abbott to Pay $670 Million to Settle Baby-Formula Litigation - WSJ
Abbott agrees to $670 million settlement of infant formula cases - The Lufkin Daily News
Abbott settles preterm formula litigation for $670 million By Investing.com - Investing.com Canada
Abbott's $670 Million Settlement Resolves Infant Formula Legal Claims - Devdiscourse
Abbott in $670M settlement for some NEC infant formula claims (ABT:NYSE) - Seeking Alpha
Abbott agrees to pay ~$670M to resolve Gill case and ~2,000 related preterm formula claims - TradingView
Abbott settles $670M lawsuits over preterm infa... - Pluang
Abbott Will Pay $670 Million to End 2,000 Infant Formula Claims - Bloomberg.com
Abbott reaches agreements to resolve a portion of litigation involving its specialty formulas for preterm infants - PR Newswire
Abbott pays $670 million to settle 2,000 baby formula claims - Crain's Chicago Business
MiniMed Ships MiniMed Flex With Abbott's Smallest Instinct Sensor - Yahoo! Finance Canada
Avricore and Abbott Labs sign UK pharmacy testing deal | 2026-08-20 | Investing News - Stockhouse
Mirae Asset Global Investments Co. Ltd. Raises Position in Abbott Laboratories $ABT - MarketBeat
Murphy Pohlad Asset Management LLC Purchases 12,140 Shares of Abbott Laboratories $ABT - MarketBeat
Citizens National Bank Trust Department Acquires 11,285 Shares of Abbott Laboratories $ABT - MarketBeat
Abbott vs. Intuitive Surgical: Is Consistent Growth Better Than Premium Growth? - Yahoo Finance
Abbott settles appeal of $495 million infant formula verdict - Investing.com
Abbott Laboratories stock outperforms competitors on strong trading day - MarketWatch
Richard W. Allen of Georgia’s 12th district makes significant trades in Abbott Laboratories and Advanced Micro Devices - Investing.com India
Abbott Laboratories (ABT) Could Be 5% Undervalued Following MiniMed Pump Launch - simplywall.st
UnitedHealth Stock And 2 Dividend Names For Investors Seeking Stability - simplywall.st
Abbott settles appeal over $495 million infant formula verdict - Reuters
Abbott Laboratories posts 4.8% sales growth in Q2 2026, driven by nutrition, diagnostics, and devices. - Pluang
Here's How Abbott's Medical Devices Arm Acts as a Growth Catalyst - The Globe and Mail
Abbott Laboratories: Diagnostics And Medical Devices Fuel Next Growth Phase (Downgrade) - Seeking Alpha
The Smartest Dividend ETF to Buy With $500 Right Now - The Globe and Mail
5 questions on Abbott’s glucose-ketone sensors - MedTech Dive
Abbott Laboratories raises earnings outlook aft... - Pluang
Invesco Nasdaq Biotech vs. Invesco Pharma: How Do These ETFs Stack Up? - The Motley Fool
Abbott Laboratories: Reasonably Valued After Surge, But Still An Attractive Buy Long-Term - Seeking Alpha
IFP Advisors Inc Purchases 176,649 Shares of Abbott Laboratories $ABT - MarketBeat
Thomasville National Bank Acquires Shares of 19,194 Abbott Laboratories $ABT - MarketBeat
Smith & Nephew drops 3.5% as finance chief quits - Proactive Investors
Allied Investment Advisors LLC Buys 17,762 Shares of Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories stock underperforms Tuesday when compared to competitors despite daily gains - MarketWatch
Abbott Laboratories stock holds above $110 as consensus target stays higher - ad-hoc-news.de
Sibionics Loses 2nd Bid At Nixing Abbott Patent - Law360
Abbott (NYSE:ABT) Valuation Focus Grows With Lingo AI Expansion - Kalkine Media
Abbott and NACHC Launch Multi-Year Initiative to Embed Nutrition Into Primary Care at Community Health Centers - Nutritional Outlook
Abbott (ABT) Stock May Be 27% Undervalued As Lingo AI Tie Up Grows - simplywall.st
Moody Lynn Lieberson & Walker LLC Has $22.52 Million Stock Position in Abbott Laboratories $ABT - MarketBeat
Prevail Innovative Wealth Advisors LLC Invests $2.83 Million in Abbott Laboratories $ABT - MarketBeat
Liberty Capital Management Inc. Invests $3.14 Million in Abbott Laboratories $ABT - MarketBeat
Merit Financial Group LLC Has $7.06 Million Holdings in Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories Stock (ABT) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.61%
0.38%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):